摘要 |
The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging and staging of CCK-2/gastrin-R-positive neoplasms in man with SPECT (technetium-99m), or PET (technetium-94m), or eventually in targeted radionuclide therapy (rhenium-188).
|